Partner Clyde Tinnen was quoted in a Reorg article, “Healthcare Mergers Dwindle Despite Increase in Sector Activity,” about an expected decline in industry deals for both health care providers and pharmaceutical companies in light of the coronavirus pandemic.
Tinnen said enforcement changes made by regulators so far in response to the spread of the coronavirus appear aimed at collaboration and conduct rather than M&A. For industry players contemplating uncertain territories, he said, “the agencies will be there to guide them on how much information can be shared without divulging prohibited competitive information such as pricing data.”
(Subscription required.)
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."